Biotech Astex Pharmaceuticals (NASDAQ: ASTX) made a huge pop today, after RBC gave the stock an upgrade to "outperform," calling it an "undiscovered gem" and raising the price target a whopping 40%. In this video, Motley Fool health-care analyst David Williamson tells investors about some potentially very exciting phase 2 data soon to be released by the company and gives us a picture of what it could mean for Astex if its trial data is as good as RBC thinks.